Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?
C Alati, M Pitea, MC Mico, V Marafioti… - Expert Review of …, 2024 - Taylor & Francis
Introduction Despite the prognosis of patients affected by acute myeloid leukemia (AML)
improved in the last decade, most patients relapse. Maintenance therapy after a …
improved in the last decade, most patients relapse. Maintenance therapy after a …
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond
Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute
myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or …
myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or …
Full CD34 Donor Chimerism Following CD34 Chimerism Directed Donor Lymphocyte Infusion Results in Reduced Relapse and Superior Overall Survival Compared …
JBL Tan, DJ Curtis, J Muirhead, M Swain, S Fleming… - Blood, 2023 - Elsevier
Introduction Peripheral blood CD34 donor chimerism (DC) is a clinically valuable method for
detecting relapse of myeloid malignancies following allogeneic hematopoietic stem cell …
detecting relapse of myeloid malignancies following allogeneic hematopoietic stem cell …